Nantahala Capital Management LLC Takes Position in Keros Therapeutics, Inc. $KROS

Nantahala Capital Management LLC bought a new position in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 1,410,419 shares of the company's stock, valued at approximately $15,091,483. Nantahala Capital Management LLC owned approximately 7.11% of Keros Therapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd grew its stake in Keros Therapeutics by 254.6% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company's stock valued at $33,000 after acquiring an additional 1,166 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in Keros Therapeutics by 149.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company's stock worth $42,000 after purchasing an additional 1,888 shares in the last quarter. Legal & General Group Plc purchased a new stake in Keros Therapeutics in the 2nd quarter worth $90,000. PDT Partners LLC bought a new position in shares of Keros Therapeutics during the 2nd quarter valued at about $122,000. Finally, Lazard Asset Management LLC bought a new position in shares of Keros Therapeutics during the 1st quarter valued at about $129,000. Institutional investors own 71.56% of the company's stock.

Insider Buying and Selling

In other Keros Therapeutics news, Director Alpna Seth sold 2,625 shares of the company's stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $10.72, for a total transaction of $28,140.00. Following the sale, the director directly owned 9,767 shares in the company, valued at $104,702.24. This represents a 21.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Lorena Raquel Lerner sold 3,568 shares of the firm's stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $10.29, for a total value of $36,714.72. Following the completion of the sale, the insider directly owned 27,559 shares of the company's stock, valued at $283,582.11. The trade was a 11.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 13,768 shares of company stock worth $144,979. Insiders own 12.60% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Zacks Research raised Keros Therapeutics from a "strong sell" rating to a "hold" rating in a report on Thursday. Weiss Ratings reissued a "sell (d-)" rating on shares of Keros Therapeutics in a research note on Wednesday, August 12th. Wells Fargo & Company cut their price target on Keros Therapeutics from $20.00 to $18.00 and set an "overweight" rating for the company in a report on Tuesday, August 4th. Wall Street Zen raised Keros Therapeutics from a "strong sell" rating to a "sell" rating in a research note on Monday, August 24th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $20.00 price objective on shares of Keros Therapeutics in a report on Tuesday, August 4th. Four investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $20.50.

Keros Therapeutics Stock Down 1.8%

Shares of NASDAQ:KROS opened at $11.03 on Friday. Keros Therapeutics, Inc. has a 52 week low of $9.69 and a 52 week high of $22.55. The stock has a market capitalization of $218.72 million, a P/E ratio of -2.98 and a beta of 0.99. The firm has a fifty day simple moving average of $10.78 and a two-hundred day simple moving average of $11.61.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its earnings results on Monday, August 3rd. The company reported ($1.45) earnings per share for the quarter, missing analysts' consensus estimates of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. On average, analysts expect that Keros Therapeutics, Inc. will post -5.27 earnings per share for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc NASDAQ: KROS is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company's research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company's lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.

Want to see what other hedge funds are holding KROS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source